カテゴリ： GlobalData, アメリカ, 企業調査

Achillion Pharmaceuticals Inc (ACHN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Achillion Pharmaceuticals Inc (ACHN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9869
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD) and chronic obstructive pulmonary disease (COPD). Achillion is headquartered in New Haven, Connecticut, the US.

Achillion Pharmaceuticals Inc (ACHN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Achillion Pharma Enters into Licensing Agreement with Ora 11
Equity Offering 12
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc – Key Competitors 20
Achillion Pharmaceuticals Inc – Key Employees 21
Achillion Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Achillion reports second quarter 2018 financial results 23
May 02, 2018: Achillion Reports First Quarter 2018 Financial Results and Management Transition 25
Feb 22, 2018: Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results 27
Nov 01, 2017: Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 29
Aug 08, 2017: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 30
May 04, 2017: Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs 33
Feb 23, 2017: Achillion Reports 2016 Fourth Quarter and Year-End Financial Results 35
Corporate Communications 37
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer 37
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer 38
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer 39
Sep 11, 2017: Achillion Announces Strengthening of Management Team 40
Jul 10, 2017: Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change 41
Product News 42
09/11/2017: Janssen to Discontinue Hepatitis C Development Program 42
02/26/2018: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy 43
Product Approvals 44
Nov 06, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 44
Clinical Trials 45
Jul 10, 2018: Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D 45
Dec 20, 2017: Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 46
Dec 18, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 47
Nov 14, 2017: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 48
Nov 01, 2017: Achillion Provides Update on ACH-4471 50
Nov 01, 2017: Achillion Provides Update on ACH-5228 52
Oct 23, 2017: Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting 53
Apr 24, 2017: Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178) 54
Apr 22, 2017: Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 55
Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria 56
Apr 06, 2017: New data for simeprevir will be presented at EASL’s International Liver Congress 2017 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharma Enters into Licensing Agreement with Ora 11
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc, Key Competitors 20
Achillion Pharmaceuticals Inc, Key Employees 21

List of Figures
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Achillion Pharmaceuticals Inc (ACHN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Air France-KLM SA：企業のM&A・事業提携・投資動向
    Air France-KLM SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Air France-KLM SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Sul America SA：企業の戦略・SWOT・財務情報
    Sul America SA - Strategy, SWOT and Corporate Finance Report Summary Sul America SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Commonwealth Scientific and Industrial Research Organisation-医療機器分野：企業M&A・提携分析
    Summary Commonwealth Scientific and Industrial Research Organisation (CSIRO) is a national science agency that conducts research in climate adaptation, bio-security, renewable and energy, farming and food production, and information technology, and mining and manufacturing services, and others. The …
  • HumanOptics AG (H9O1)：企業の財務・戦略的SWOT分析
    Summary HumanOptics AG (HumanOptics), a subsidiary of Medipart AG, is a medical device company that develops, manufactures and distributes intraocular implants for opthalmic surgeries. The company offers products such as intraocular lenses, artificiallris, capsular tension rings and cornea implants. …
  • Hydrogenics Corp (HYG)：企業の財務・戦略的SWOT分析
    Hydrogenics Corp (HYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sampo plc：企業のM&A・事業提携・投資動向
    Sampo plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sampo plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Novavax Inc (NVAX)-製薬・医療分野：企業M&A・提携分析
    Summary Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccine …
  • Lupin Ltd (LUPIN)：企業の財務・戦略的SWOT分析
    Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Zimmer Biomet Holdings Inc (ZBH)：医療機器：M&Aディール及び事業提携情報
    Summary Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company with focus on musculoskeletal healthcare. The company designs, manufactures, and markets orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and tho …
  • Alps Industries Ltd.：企業の戦略・SWOT・財務情報
    Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Plantic Technologies Ltd：企業の戦略的SWOT分析
    Plantic Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Carrizo Oil & Gas Inc (CRZO)：石油・ガス：M&Aディール及び事業提携情報
    Summary Carrizo Oil & Gas Inc (Carrizo) is an independent oil and gas company, which carries out exploration, development and production of oil and natural gas from several resources plays. It has presence in the Eagle Ford Shale in South Texas and the Delaware Basin in West Texas. The company princ …
  • Beautiful Brands International, LLC：企業の戦略・SWOT・財務分析
    Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report Summary Beautiful Brands International, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Chicago Bridge & Iron Company NV (CBI)：電力：M&Aディール及び事業提携情報
    Summary Chicago Bridge & Iron Company NV (CB&I) is a provider of technology and infrastructure solutions. Its services include conceptual design, technology, engineering, procurement, modularization, construction, fabrication, commissioning, maintenance, program management and environmental services …
  • Industrial Bank Of Korea
    Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Energy Fuels Inc (EFR)：企業の財務・戦略的SWOT分析
    Energy Fuels Inc (EFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Diamondback Energy Inc (FANG)：企業の財務・戦略的SWOT分析
    Summary Diamondback Energy Inc (Diamondback Energy) operates as an oil and gas company that offers exploration and development programs. The company acquires, develops, explores and exploits unconventional, onshore oil and natural gas reserves in Permian Basin in West Texas. It develops the reserves …
  • Mapfre S.A. (MAP)：企業の財務・戦略的SWOT分析
    Mapfre S.A. (MAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Philippine National Bank
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Prologis, Inc.：企業のM&A・事業提携・投資動向
    Prologis, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prologis, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆